Volume | 1,397,908 |
|
|||||
News | - | ||||||
Day High | 4.71 | Low High |
|||||
Day Low | 4.47 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Mersana Therapeutics Inc | MRSN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.49 | 4.47 | 4.71 | 4.48 | 4.49 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
9,765 | 1,397,908 | $ 4.57 | $ 6,394,358 | - | 0.8014 - 9.62 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:59:53 | 39 | $ 4.48 | USD |
Mersana Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
542.22M | 121.30M | - | 36.86M | -171.67M | -1.42 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Mersana Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRSN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.85 | 5.11 | 4.22 | 4.46 | 2,046,043 | -0.37 | -7.63% |
1 Month | 5.60 | 6.2801 | 4.22 | 5.26 | 3,029,322 | -1.12 | -20.00% |
3 Months | 2.18 | 6.2801 | 2.15 | 4.23 | 2,425,922 | 2.30 | 105.50% |
6 Months | 1.26 | 6.2801 | 1.065 | 2.97 | 2,168,777 | 3.22 | 255.56% |
1 Year | 4.19 | 9.62 | 0.8014 | 2.74 | 3,513,087 | 0.29 | 6.92% |
3 Years | 16.49 | 18.08 | 0.8014 | 4.33 | 1,923,083 | -12.01 | -72.83% |
5 Years | 5.01 | 29.09 | 0.8014 | 6.84 | 1,460,254 | -0.53 | -10.58% |
Mersana Therapeutics Description
Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines. |